Inhibitors of phosphodiesterase 5 (PDE5) – sildenafil citrate (Viagra; Pfizer) and vardenafil hydrochloride (Levitra; Bayer/GlaxoSmithKline) – approved for the treatment of erectile dysfunction and pulmonary arterial hypertension also rescue the loss of cystic fibrosis (CF) chloride channel function and the mislocalization of F508del-CFTR in affected tissues in CF. Can PDE5 inhibitors provide a therapeutic strategy which combines ability to correct the basic ion transport defect and to control de-regulated lung inflammation in CF?

Subjects:
Immunology & Inflammation, Molecular Bases of Health & Disease, Molecular Interactions
© 2017 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society
2017
You do not currently have access to this content.